Acura Pharmaceuticals, Inc. · Palatine, IL United States (NASDAQ: ACUR)
| 616 N. North Ct., Ste. 120 | Phone: 847-705-7709 |
| Palatine, IL | Fax: 847-705-5399 |
| 60067 | |
| United States | 
Map This Company |
Acura Pharmaceuticals, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Acura Pharmaceuticals is working to provide accurate drug dosages without allowing for abuse. The company has developed a technology to add abuse-deterring agents to commonly abused pharmaceuticals. If a drug with these agents (what Acura calls Aversion Technology) is crushed and inhaled, certain ingredients will cause nasal irritation, and if an abuser attempts to dissolve the powder, it will form a non-injectable gel. Other Aversion Technology oral ingredients can cause stomach discomfort if taken in excess. Lead product candidate Oxecta, which combines Aversion Technology with the commonly abused opioid painkiller oxycodone HCl, gained
Acura Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ACUR Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2009 Employees | 15 |
Executives
15 executives listed for Acura Pharmaceuticals, Inc.'s Palatine, IL location.
| Chairman | Richard Markham | |
|---|---|---|
| Interim President and CEO | Robert Jones | |
| SVP, CFO, and Secretary | Peter Clemens |